,,iv  #aac? ,,congress  #b;d ,session   
,h4 ,,res4 #ebh  ,,9 ,,! ,,h\se ,,(     
,,repres5tatives  ,m>* #bg1 #bjad ,mr4  
,ba*us 7= himself1 ,mr4 ,rangel1 ,mr4   
,higg9s1 ,mr4 ,honda1 ,mr4 ,johnson (   
,georgia1 ,mrs4 ,capito1 ,ms4 ,norton1  
,mr4 ,rice ( ,s\? ,c>ol9a1 ,mr4 ,ha/+s (
 ,florida1 ,mr4 ,danny ,k4 ,davis (     
,ill9ois1 & ,mr4 ,byrne7 submitt$ !     
foll[+ resolution2 :i* 0 ref]r$ to !    
,committee on ,ov]sight & ,gov]nm5t     
,re=m  ,,resolution  ,express+ support =
 designation ( ,m>* #bjad z ,national   
,multiple ,myeloma ,aw>5ess ,mon?4      
,:]eas multiple myeloma 7or myeloma7 is 
a canc] ( plasma cells 9 ! bone m>r[ &  
is call$ 8multiple0 because x c occur at
 v>i\s sites 9 ! body2 ,:]eas multiple  
myeloma causes a v>iety ( adv]se heal?  
effects1 includ+ a weak5$ immune sy/em1 
anemia1 kidney damage1 & bone           
det]ioration2 ,:]eas multiple myeloma is
 ! second mo/ common blood canc]        
worldwide2 ,:]eas multiple myeloma      
curr5tly affects m ?an #ajj1jjj p 9 !   

,unit$ ,/ates1 ) ab\t #bb1cej new cases 
diagnos$ & #aj1gaj dea?s f ! disease 9  
#bjac accord+ to ! ,national ,canc]     
,in/itute's ,surveillance1              
,epidemiology1 & ,end ,results ,program2
 ,:]eas once pr$om9ately f\nd among ^?  
#fe & ov]1 :]e x cont9ues to be mo/     
frequ5tly diagnos$1 multiple myeloma is 
increas+ly be+ id5tifi$ 9 y\ng] age     
individuals includ+ ^? 9 _! #cjs1 #djs1 
& #ejs2 ,:]eas multiple myeloma is almo/
 twice z likely to occur among          
,african-,am]icans & is "o ( ! lead+    
causes ( canc] dea?s among              
,african-,am]icans1 ) sci5tific und]/&+ 
( ! disp>ity rema9+ unkn[n2 ,:]eas !    
cause ( multiple myeloma is n kn[n1 )   
robu/ rese>* be+ p]=m$ 9 ! ,unit$ ,/ates
 & int]nationally into pot5tial g5etic1 
environm5tal1 & o!r risk factors2 ,:]eas
 rec5t ye>s h se5 ! developm5t ( new    
drugs & treatm5ts t h improv$ life      
expectancies & significantly enhanc$ !  
quality ( life = pati5ts2 ,:]eas        
additional new drugs & !rapies are 9 !  

rese>* phase1 ) pati5t enrollm5t 9      
cl9ical trials play+ an important role 9
 det]m9+ safe & effective treatm5ts2    
,:]eas und]/&+ & treatm5t ( multiple    
myeloma has be5 greatly fur!r$ by ! role
 ( advocacy initiatives promot+ aw>5ess1
 education1 rese>*1 pe] review1 &       
collaboration & su* ef=ts are to be     
highly comm5d$2 ,:]eas great] aw>5ess ( 
multiple myeloma on ! "p ( cl9icians & !
 g5]al public c lead to e>li] detection 
& treatm5t1 improv+ heal? outcomes &    
br++ com=t to pati5ts & _! families2 &  
,:]eas ,m>* #bjad w\ld be an appropriate
 mon? to designate z ,national ,multiple
 ,myeloma ,aw>5ess ,mon?3 ,n[1 !re=e1 be
 x  ,t ! ,h\se ( ,repres5tatives        
supports ! designation ( 8,national     
,multiple ,myeloma ,aw>5ess ,mon?0 to   
increase public k ( ?is disease &       
advance ! vision ( f9d+ a cure =        
multiple myeloma4